Department of Molecular Biology in College of Basic Medical Sciences and Institute of Pediatrics in The First Hospital of Jilin University, Norman Bethune Health Science Center, Jilin University, Changchun, 130021, Jilin, China.
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Appl Microbiol Biotechnol. 2018 Dec;102(24):10541-10550. doi: 10.1007/s00253-018-9361-2. Epub 2018 Oct 18.
Mixed infection of porcine circovirus type 2 (PCV2) and foot-and-mouth disease virus (FMDV) is devastating to swine populations. To develop an effective vaccine that can protect the pigs from the infection of PCV2 and FMDV, we used the neutralizing B cell epitope region (aa 135-160) of FMDV to replace the regions aa 123-151 and aa 169-194 of the PCV2b Cap protein to generate a recombinant protein designated as Capfb. The Capfb protein was expressed in Escherichia coli system and the purified Capfb protein assembled into virus-like particles (VLPs) through dialysis. The ability of the Capfb protein to induce effective immune response against FMDV and PCV2b was tested in mice and guinea pigs. The results showed that the Capfb-VLPs could elicit anti-PCV2b and anti-FMDV antibody response in mice and guinea pigs without inducing antibodies against decoy epitope. Moreover, the Capfb-VLPs could enhance the percentage and activation of B cells in lymph nodes when the mice were stimulated with inactivated FMDV or PCV2b. These data suggested that the Capfb-VLPs could be an efficacious candidate antigen for developing a novel PCV2b-FMDV bivalent vaccine.
猪圆环病毒 2 型（PCV2）和口蹄疫病毒（FMDV）的混合感染对猪群是毁灭性的。为了开发一种有效的疫苗，可以保护猪免受 PCV2 和 FMDV 的感染，我们使用 FMDV 的中和 B 细胞表位区域（aa135-160）替换 PCV2b Cap 蛋白的 aa123-151 和 aa169-194 区域，生成了一种名为 Capfb 的重组蛋白。Capfb 蛋白在大肠杆菌系统中表达，并通过透析将纯化的 Capfb 蛋白组装成病毒样颗粒（VLPs）。在小鼠和豚鼠中测试了 Capfb 蛋白诱导针对 FMDV 和 PCV2b 的有效免疫反应的能力。结果表明，Capfb-VLPs 可以在小鼠和豚鼠中诱导针对 PCV2b 和 FMDV 的抗体反应，而不会诱导针对诱饵表位的抗体。此外，Capfb-VLPs 可以在刺激灭活的 FMDV 或 PCV2b 时增强淋巴结中 B 细胞的百分比和激活。这些数据表明，Capfb-VLPs 可能是开发新型 PCV2b-FMDV 二价疫苗的有效候选抗原。
